UK Markets closed

ImmunoGen, Inc. (IMGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.90+0.07 (+1.20%)
At close: 4:00PM EDT
5.90 0.00 (0.00%)
After hours: 04:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5N/A
Enterprise value 3N/A
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7N/A

Trading information

Stock price history

Beta (5Y monthly) 1.35
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 310.88
52-week low 34.97
50-day moving average 35.85
200-day moving average 36.29

Share statistics

Avg vol (3-month) 31.31M
Avg vol (10-day) 3971.73k
Shares outstanding 5199.94M
Implied shares outstanding 6N/A
Float 8180.58M
% held by insiders 10.55%
% held by institutions 192.58%
Shares short (27 May 2021) 420.74M
Short ratio (27 May 2021) 49.5
Short % of float (27 May 2021) 411.72%
Short % of shares outstanding (27 May 2021) 410.37%
Shares short (prior month 29 Apr 2021) 420.9M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Mar 2021

Profitability

Profit margin -36.62%
Operating margin (ttm)-19.91%

Management effectiveness

Return on assets (ttm)-5.20%
Return on equity (ttm)-109.61%

Income statement

Revenue (ttm)134.72M
Revenue per share (ttm)0.73
Quarterly revenue growth (yoy)18.20%
Gross profit (ttm)17.71M
EBITDA -24.7M
Net income avi to common (ttm)-49.34M
Diluted EPS (ttm)-0.27
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)283.12M
Total cash per share (mrq)1.42
Total debt (mrq)23.09M
Total debt/equity (mrq)24.53
Current ratio (mrq)2.38
Book value per share (mrq)0.47

Cash flow statement

Operating cash flow (ttm)-94.93M
Levered free cash flow (ttm)18.43M